Skip to main content

Table 1 Patients inclusion and exclusion criteria of the study.

From: A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation

≥18 years Patients with prior history of type 1 or type 2 diabetes
Newly diagnosed NODAT defined by pathologic OGTT (2 h, 75 mg glucose): glucose ≥200 mg/dL Body mass index (BMI) > 40 kg/m 2
- Pregnancy
Renal transplantation (deceased or living donor) and treatment with the standard immunosuppressionat our center, consisting of a triple therapy with tacrolimusor cyclosporine A, mycophenolatemofetil, and prednisone Severe renal impairment (GFR < 30 mL/min./1.73 m2)
Stable graft function for more than 6 months post transplant Severe liver impairment (ASAT/ALAT levels over threefold elevated compared to reference values)
Informed consent of the patient Severe blood glucose elevation with the need for insulin therapy or